AB
The startup has developed a non-engineered, tumor-agnostic cellular therapy platform that leverages immune cells to generate effective anti-tumor vaccines. This technology enables physicians to treat various cancers more effectively by enhancing the body's natural immune response against tumors.
Updated 3 months ago
Funding
$21.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup has developed a non-engineered, tumor-agnostic cellular therapy platform that leverages immune cells to generate effective anti-tumor vaccines. This technology enables physicians to treat various cancers more effectively by enhancing the body's natural immune response against tumors.